Company Overview
| Stock Name | Microtech Med-B |
|---|---|
| Stock Code | 02235 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 專注於糖尿病管理,提供糖尿病治療及糖尿病監測醫療器械(包括貼敷式胰島素泵系統、持續血糖監測系統及血糖監測系統等),以在中國和全球範圍內優化糖尿病的管理方式。 |
| Listing Date | 2021-10-19 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國浙江省杭州市余杭區倉前街道留澤街108號 |
| Business Address (Hong Kong) | 中國香港灣仔皇后大道東248號大新金融中心40樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | microtechmd.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 30.50 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 100 shares |
| Entry Threshold | HK$ 3,050 |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2021-10-06 to 2021-10-11 |
| Global Offering Shares | 63,529,500 shares |
| HK Public Offer Shares (Initial) | 6,353,000 shares (10.0%) |
| Public Offer Lots (Initial) | 63,530lots (Pool A31,765lots,Pool B31,765lots) |
| International Placing Shares (Initial) | 57,176,500 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 423,529,500 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 61.5% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 1,937,649,750 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 100 | HK$ 3,050 |
| 2 lots | 200 | HK$ 6,100 |
| 3 lots | 300 | HK$ 9,150 |
| 4 lots | 400 | HK$ 12,200 |
| 5 lots | 500 | HK$ 15,250 |
| 6 lots | 600 | HK$ 18,300 |
| 7 lots | 700 | HK$ 21,350 |
| 8 lots | 800 | HK$ 24,400 |
| 9 lots | 900 | HK$ 27,450 |
| 10 lots | 1,000 | HK$ 30,500 |
| 15 lots | 1,500 | HK$ 45,750 |
| 20 lots | 2,000 | HK$ 61,000 |
| 25 lots | 2,500 | HK$ 76,250 |
| 30 lots | 3,000 | HK$ 91,500 |
| 35 lots | 3,500 | HK$ 106,750 |
| 40 lots | 4,000 | HK$ 122,000 |
| 45 lots | 4,500 | HK$ 137,250 |
| 50 lots | 5,000 | HK$ 152,500 |
| 60 lots | 6,000 | HK$ 183,000 |
| 70 lots | 7,000 | HK$ 213,500 |
| 80 lots | 8,000 | HK$ 244,000 |
| 90 lots | 9,000 | HK$ 274,500 |
| 100 lots | 10,000 | HK$ 305,000 |
| 200 lots | 20,000 | HK$ 610,000 |
| 300 lots | 30,000 | HK$ 915,000 |
| 400 lots | 40,000 | HK$ 1,220,000 |
| 500 lots | 50,000 | HK$ 1,525,000 |
| 600 lots | 60,000 | HK$ 1,830,000 |
| 700 lots | 70,000 | HK$ 2,135,000 |
| 800 lots | 80,000 | HK$ 2,440,000 |
| 1,000 lots | 100,000 | HK$ 3,050,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 2,000 lots | 200,000 | HK$ 6,100,000 |
| 3,000 lots | 300,000 | HK$ 9,150,000 |
| 5,000 lots | 500,000 | HK$ 15,250,000 |
| 6,000 lots | 600,000 | HK$ 18,300,000 |
| 7,000 lots | 700,000 | HK$ 21,350,000 |
| 20,000 lots | 2,000,000 | HK$ 61,000,000 |
| 31,765 lots | 3,176,500 | HK$ 96,883,250 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| HK Market Cap | HK$ 1.17B |
| Est. Threshold | HK$ 9.39B |
| Analysis Result | HK market cap below threshold, need +705% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 12,917,649,750 |
|---|---|
| H-Share Market Cap (at Offer Price) | HK$ 1,937,649,750 |
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 虧損人民幣121.25百萬元 |
| Period-End Cash Balance | 人民幣549.8百萬元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2019 | 2020 |
|---|---|---|
| Revenue | 51,863 | 75,277 |
| Cost of sales | -27,780 | -38,733 |
| Gross profit | 24,083 | 36,544 |
| Other income and gains, net | 8,716 | 27,663 |
| Selling and distribution expenses | -27,003 | -55,059 |
| Administrative expenses | -33,615 | -45,758 |
| Operating profit | -78,303 | -120,942 |
| Net finance costs | -311 | -308 |
| Profit before tax | -78,614 | -121,250 |
| Income tax expense | 0 | 0 |
| Profit for the year | -78,614 | -121,250 |
| Profit attributable to owners | -78,614 | -121,009 |
Balance Sheet
| Item | 2019 | 2020 | 2021-04 |
|---|---|---|---|
| Cash and cash equivalents | 41,428 | 549,800 | |
| Trade and bills receivables | 7,386 | 10,359 | |
| Inventories | 8,638 | 18,423 | |
| Total current assets | 195,549 | 688,276 | |
| Total current liabilities | 47,953 | 48,757 | |
| Total equity | 216,790 | 728,517 | |
| Equity attributable to owners | 216,790 | 728,517 | |
| Interest-bearing borrowings | 10,012 | 0 | 0 |
Cash Flow Statement
| Item | 2019 | 2020 | 2021-04 |
|---|---|---|---|
| Net cash from operating activities | -17,954 | -9,575 | |
| Net cash from investing activities | -95,141 | -1,222 | |
| Net cash from financing activities | 100,876 | 511,276 | |
| Net increase in cash | -12,219 | 500,479 | |
| Depreciation of PP&E | 1,106 | 3,287 | 1,948 |
| Depreciation of right-of-use assets | 867 | 493 | 105 |
| Amortisation of intangible assets | 1,457 | 1,704 | 564 |
| Purchase of PP&E | -28,571 | -25,655 | -3,772 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 30.5 |
|---|---|
| First Day Open | HK$ 31.0 |
| First Day Change | -73.97% |
| First Day Volume | 6776600.0 |
| First Day Turnover | 207865000.0 |
| Use of Proceeds | 1、31%(或約562.7百萬港元)分配予我們的核心產品;
2、35%(或約635.3百萬港元)分配予我們的持續血糖監測系統;
3、11%(或約199.7百萬港元)將分配至我們第二代貼敷式胰島素泵系統的臨床 前研究、臨床試驗、注冊、生產及商業化;
4、8%(或約145.2百萬港元)將分配至我們其他產品及在研產品的臨床前研 究、臨床試驗、注冊、生產及商業化;
5、5%(或約90.8百萬港元)將用于為建立我們基于云端大數據的糖尿病管理平 臺提供資金;
6、10%(或約181.5百萬港元)將分配用于營運資金及其他一般公司用途。 |
Underwriting Syndicate
Joint Bookrunners (3)
Joint Lead Managers (3)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Boyu Capital Opportunities Master Fund | 77,832,950 HKD | — | 4.00% | — | 6 months | 2022-04-19 |
| 2 | Hudson Bay Master Fund LTD | 97,288,900 HKD | — | 5.00% | — | 6 months | 2022-04-19 |
| 3 | Invesco Advisers, Inc. | 272,413,800 HKD | — | 14.10% | — | 6 months | 2022-04-19 |
| 4 | Lake Bleu Prime Healthcare Master Fund Limited | 77,832,950 HKD | — | 4.00% | — | 6 months | 2022-04-19 |
| 5 | LAV Star Limited | 97,288,900 HKD | — | 5.00% | — | 6 months | 2022-04-19 |
| 6 | Octagon Investments Master Fund LP | 77,832,950 HKD | — | 4.00% | — | 6 months | 2022-04-19 |
| 7 | OrbiMed Genesis Master Fund,L.P. | 62,265,750 HKD | — | 3.20% | — | 6 months | 2022-04-19 |
| 8 | Sage Partners Master Fund | 62,265,750 HKD | — | 3.20% | — | 6 months | 2022-04-19 |
| 9 | Springhill Master Fund Limited | 97,288,900 HKD | — | 5.00% | — | 6 months | 2022-04-19 |
| 10 | Tencent Mobility Limited | 77,832,950 HKD | — | 4.00% | — | 6 months | 2022-04-19 |
| 11 | UBS Asset Management (Singapore) Ltd. | 194,580,850 HKD | — | 10.00% | — | 6 months | 2022-04-19 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 鄭攀 | — |
| Company Secretary | 朵波、張夢弛 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 鄭攀博士直接及通過杭州研泰、杭州衡泰控制本公司約34.17%已發行總股本(上市前為控股股東,上市後為單一最大股東集團);其他主要股東包括QM32 Limited(9.46%)、浙江九仁資本管理有限公司(7.79%)、施毅博士(7.12%)、江蘇疌泉醴澤健康產業創業投資基金(6.53%)等。 |
|---|




